ACE2 activator diminazene aceturate reduces adiposity but preserves lean mass in young and old rats.
ACE2 activator diminazene aceturate reduces adiposity but preserves lean mass in young and old rats.
复制标题
DOI：
10.1016/j.exger.2018.07.008
复制
发表时间：
2018-10-01
影响因子：
3.9
通讯作者：
Carter CS
中科院分区：
文献类型：
--
作者：
Bruce EB;Sakarya Y;Kirichenko N;Toklu HZ;Sumners C;Morgan D;Tümer N;Scarpace PJ;Carter CS
The obesity epidemic is multi-generational and is particularly debilitating in the aging population, necessitating the use of pharmaceutical interventions. Recent evidence suggests that increasing the activity of the angiotensin converting enzyme-2 [ACE2]/angiotensin-(1–7)[Ang-(1–7)]/Mas receptor (MasR) axis in obese animal models leads to significant reductions in body weight. It was hypothesized that activation of ACE2 via diminazene aceturate (DIZE) will significantly reduce body weight of rats fed a high fat diet. Young and old (4 and 23 months, respectively) male Fisher 344 x Brown Norway rats were fed 60% high fat diet for one week, and subsequently given either 15mg/kg/day DIZE s.c. or vehicle for three weeks. DIZE treatment resulted in a significant reduction of food intake and body weight in both young and old animals. However, that decrease was so dramatic in the older animals that they all nearly stopped eating. Interestingly, the TD-NMR assessments revealed that the weight-loss was primarily a result of decreased body fat percentage, with a relative preservation of lean mass. Tissue weights confirm the significant loss of white adipose tissue (WAT), with no change in muscle weights. Gene expression and serum ACE2 activity analyses implied that increased activation of the ACE2/Ang-(1–7)/MasR axis plays a role in reducing fat mass. Collectively, our results suggest that DIZE may be a useful tool in the study of obesity; however, caution is recommended when using this compound in older animals due to severe anorectic effects, although there is a mechanism by which muscle is preserved.
登录
查看更多内容
DOI：
10.1161/hypertensionaha.111.176636
发表时间：
2011-12
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Xiao L;Gao L;Lazartigues E;Zucker IH
通讯作者：
Zucker IH
DOI：
10.1001/jama.2014.732
发表时间：
2014-02-26
期刊：
JAMA
影响因子：
--
作者：
Ogden CL;Carroll MD;Kit BK;Flegal KM
通讯作者：
Flegal KM
DOI：
10.1152/ajprenal.00655.2013
发表时间：
2014-04-01
影响因子：
4.2
作者：
Mori, Jun;Patel, Vaibhav B.;Oudit, Gavin Y.
通讯作者：
Oudit, Gavin Y.
DOI：
10.1161/hypertensionaha.115.05185
发表时间：
2015-07
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Bennion DM;Haltigan EA;Irwin AJ;Donnangelo LL;Regenhardt RW;Pioquinto DJ;Purich DL;Sumners C
通讯作者：
Sumners C
影响因子：
4.9
作者：
Olsen, Michael Hecht;Wachtell, Kristian;Wedel, Hans
通讯作者：
Wedel, Hans